|
|
|
|
|
Cosmeceutical therapies on the horizon
|
In a presentation at the Fall Clinical Dermatology Conference held on Saturday in Las Vegas, Diane Berson, M.D., outlined trends and new ingredients in oral and topical cosmeceuticals. |
|
|
More new therapies under study for underarm sweat
|
Qbrexza was approved earlier this year for primary axillary hyperhidrosis. And, now, other treatments are under study. In his presentation at this week’s Fall Clinical Dermatology Conference in Las Vegas, Dr. David Pariser summarizes the latest research. |
|
|
Treatment options for benign lesions
|
Patients are increasingly seeking to have benign lesions removed and today, there are a number of treatment options available to safely and effectively remove unwanted lesions. Suneel Chilukuri, M.D., reviewed these options during a presentation at the Fall Clinical Dermatology Conference held this week in Las Vegas. |
|
|
Four effective anti-IL 23 drugs for psoriasis
|
Two approved and two pending anti-IL 23 drugs offer an opportunity for moderate to severe psoriasis patients to regain their lives, according to researchers presenting at the 2018 Fall Clinical Dermatology Conference. |
|
|